Treatment of cancer using a CD123 chimeric antigen receptor
The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a CD123 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said CD123 binding domain comprises a heavy chain variable domain region comprising a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3) and light chain variable domain region comprising a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3), wherein:
(a) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 486, 491, 496, 501, 506, and 511, respectively; or
(ii) SEQ ID NOs: 516, 521, 526, 531, 536, and 541, respectively;
(b) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 488, 493, 498, 503, 508, and 513, respectively; or
(ii) SEQ ID NOs: 518, 523, 528, 533, 538, and 543, respectively; or
(c) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2 and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 489, 494, 499, 504, 509, and 514, respectively; or
(ii) SEQ ID NOs: 519, 524, 529, 534, 539, and 544, respectively.
2. The isolated nucleic acid molecule of claim 1 , which encodes a CAR comprising:
(i) the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278; or
(iii) an amino acid sequence with 95-99% identity to the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278.
3. The isolated nucleic acid molecule of claim 1 , which encodes a CAR comprising:
(i) the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216, 218, or 219;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216, 218, or 219; or
(iii) an amino acid sequence with 95-99% identity to the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216, 218, or 219.
4. The isolated nucleic acid molecule of claim 1 , which encodes a CAR comprising the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278, and the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216, 218, or 219.
5. The isolated nucleic acid molecule of claim 1 , wherein:
(a) the encoded CD123 binding domain comprises:
(i) the amino acid sequence of any of SEQ ID NO: 478, 483, or 485;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NO: 478, 483, or 485;
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NO: 478, 483, or 485;
(iv) the amino acid sequence of any of SEQ ID NO: 157, 159, or 160;
(v) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NO: 157, 159, or 160; or
(vi) an amino acid sequence with 95-99% identity to any of SEQ ID NO: 157, 159, or 160;
or
(b) the nucleic acid molecule comprises a nucleotide sequence selected from a group consisting of SEQ ID NO: 482 or 484, or a nucleotide sequence with 95-99% identity thereto, which encodes the CD123 binding domain.
6. The isolated nucleic acid molecule of claim 1 , wherein:
(i) the encoded CAR includes a transmembrane domain that comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154;
(ii) the encoded transmembrane domain comprises the amino acid sequence of SEQ ID NO: 6, an amino acid sequence comprises at least one, two, or three modifications but not more than 20, 10, or 5 modifications to the amino acid sequence of SEQ ID NO:6, or an amino acid sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:6; or
(iii) the nucleic acid sequence encoding the transmembrane domain comprises the nucleotide sequence of SEQ ID NO:17, or a nucleotide sequence with 95-99% identity thereto.
7. The isolated nucleic acid molecule of claim 1 , wherein the encoded CD123 binding domain is connected to the transmembrane domain by a hinge region, wherein:
(i) the encoded hinge region comprises the amino acid sequence of SEQ ID NO:2, or an amino acid sequence comprising at least one, two, or three modifications, but no more than 20, 10, or 5 modifications, or an amino acid sequence with 95-99% identity thereto; or
(ii) the nucleic acid sequence encoding the hinge region comprises the nucleotide sequence of SEQ ID NO: 13, or a nucleotide sequence with 95-99% identity thereto.
8. The isolated nucleic acid molecule of claim 1 , wherein the encoded intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises:
(i) a functional signaling domain obtained from a protein selected from the group consisting of a MHC class I molecule, a TNF receptor protein, an Immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocytic activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11 c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, and CD19a; or
(ii) the amino acid sequence of SEQ ID NO:7; an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications to the amino acid sequence of SEQ ID NO:7; or an amino acid sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7.
9. The isolated nucleic acid molecule of claim 8 , wherein the nucleic acid sequence encoding the costimulatory domain comprises the nucleotide sequence of SEQ ID NO:18, or a nucleotide sequence with 95-99% identity thereto.
10. The isolated nucleic acid molecule of claim 1 , wherein the encoded intracellular signaling domain comprises:
(i) a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta;
(ii) the amino acid sequence of SEQ ID NO: 7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; or an amino acid sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; or
(iii) the amino acid sequence of SEQ ID NO:7 and the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.
11. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid sequence encoding the intracellular signaling domain comprises the nucleotide sequence of SEQ ID NO:18, or a nucleotide sequence with 95-99% identity thereto, and/or the nucleotide sequence of SEQ ID NO:20 or SEQ ID NO:21, or a nucleotide sequence with 95-99% identity thereto.
12. The isolated nucleic acid molecule of claim 1 , which encodes a CAR comprising:
(i) the amino acid sequence of any of SEQ ID NOs: 98, 100, or 101;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NOs: 98, 100, or 101; or
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NOs: 98, 100, or 101.
13. The isolated nucleic acid molecule of claim 1 , comprising the nucleotide sequence of any of SEQ ID NOs: 39, 41, or 42, or a nucleotide sequence with 95-99% identity to any of SEQ ID NOs: 39, 41, or 42.
14. An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR comprises a CD123 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said CD123 binding domain comprises a heavy chain variable domain region comprising a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3) and light chain variable domain region comprising a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3), wherein:
(a) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 486, 491, 496, 501, 506, and 511, respectively; or
(ii) SEQ ID NOs: 516, 521, 526, 531, 536, and 541, respectively;
(b) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 488, 493, 498, 503, 508, and 513, respectively; or
(ii) SEQ ID NOs: 518, 523, 528, 533, 538, and 543, respectively; or
(c) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 489, 494, 499, 504, 509 and 514, respectively; or
(ii) SEQ ID NOs: 519, 524, 529, 534, 539, and 544, respectively.
15. The isolated CAR polypeptide of claim 14 , comprising:
(i) the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278; or
(iii) an amino acid sequence with 95-99% identity to the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278.
16. The isolated CAR polypeptide of claim 14 , comprising:
(i) the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216 218, or 219;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216, 218, or 219; or
(iii) an amino acid sequence with 95-99% identity to the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216, 218, or 219.
17. The isolated CAR polypeptide of claim 14 , comprising the amino acid sequence of the light chain variable region of SEQ ID NO: 275, 277, or 278, and the amino acid sequence of the heavy chain variable region of SEQ ID NO: 216, 218, or 219.
18. The isolated CAR polypeptide of claim 14 , comprising:
(i) the amino acid sequence of any of SEQ ID NO: 478, 483, or 485;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NO: 478, 483, or 485;
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NO: 478, 483, or 485;
(iv) the amino acid sequence of any of SEQ ID NO: 157, 159, or 160;
(v) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NO: 157, 159, or 160; or
(vi) an amino acid sequence with 95-99% identity to any of SEQ ID NO: 157, 159, or 160.
19. The isolated CAR polypeptide of claim 14 , wherein the transmembrane domain comprises a transmembrane domain from a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154.
20. The isolated CAR polypeptide of claim 14 , wherein the transmembrane domain comprises:
(i) the amino acid sequence of SEQ ID NO: 6;
(ii) an amino acid sequence comprising at least one, two, or three modifications but not more than 20, 10, or 5 modifications to the amino acid sequence of SEQ ID NO:6, or
(iii) a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:6.
21. The isolated CAR polypeptide of claim 14 , wherein the CD123 binding domain is connected to the transmembrane domain by a hinge region, wherein the hinge region comprises SEQ ID NO: 2, or a sequence with 95-99% identity thereto.
22. The isolated CAR polypeptide of claim 14 , wherein the encoded intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises:
(i) a functional signaling domain obtained from a protein selected from the group consisting of a MHC class I molecule, a TNF receptor protein, an Immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocytic activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11 c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, and CD19a; or
(ii) the amino acid sequence of SEQ ID NO:7, or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications to the amino acid sequence of SEQ ID NO:7, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7.
23. The isolated CAR polypeptide of claim 14 , wherein the intracellular signaling domain comprises:
(i) a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta;
(ii) the amino acid sequence of SEQ ID NO: 7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; or an amino acid sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; or
(iii) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO:7 and the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the amino acid sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.
24. The isolated CAR polypeptide of claim 14 , comprising:
(i) the amino acid sequence of any of SEQ ID NOs: 98, 100, or 101;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NOs: 98, 100, or 101; or
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NOs: 98, 100, or 101.
25. A vector comprising the nucleic acid molecule of claim 1 , wherein the vector is a DNA vector, an RNA vector, a plasmid, a lentivirus vector, adenoviral vector, or a retrovirus vector.
26. An immune effector cell comprising the nucleic acid molecule of claim 1 .
27. A method of making an immune effector cell, comprising transducing the immune effector cell with the nucleic acid molecule of claim 1 .
28. A method of generating a population of RNA engineered cells, comprising introducing an in vitro transcribed RNA or synthetic RNA into a cell, wherein the RNA comprises the nucleic acid molecule of any of claim 1 .
29. A method of providing an anti-tumor immunity in a mammal, comprising administering to the mammal an effective amount of an immune effector cell, comprising the nucleic acid molecule of claim 1 .
30. A method of treating a mammal having a disease associated with expression of CD123, comprising administering to the mammal an effective amount of an immune effector cell, comprising the nucleic acid molecule of claim 1 .
31. A method of preventing a CD19-negative cancer relapse in a mammal, comprising administering to the mammal an effective amount of an immune effector cell, comprising the nucleic acid of claim 1 .
32. A method of conditioning a subject prior to cell transplantation comprising administering to the subject an effective amount of an immune effector cell comprising the CAR nucleic acid molecule of claim 1 .
33. A CD123 binding domain comprising a heavy chain variable domain region comprising a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3), and light chain variable domain region comprising a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3), wherein:
(a) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 486, 491, 496, 501, 506, and 511, respectively; or
(ii) SEQ ID NOs: 516, 521, 526, 531, 536, and 541, respectively;
(b) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 488, 493, 498, 503, 508, and 513, respectively; or
(ii) SEQ ID NOs: 518, 523, 528, 533, 538, and 543, respectively; or
(c) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 sequences comprise the amino sequences of:
(i) SEQ ID NOs: 489, 494, 499, 504, 509, and 514, respectively; or
(ii) SEQ ID NOs: 519, 524, 529, 534, 539, and 544, respectively.